Hugo Akabane, MD
Hematology · Portland, ORNPI 1982010583
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Johnson & Johnson at 44.5% of the total. Reporting peaked in 2019 at $5,077 and has fallen 90.1% since, to $503 in 2025.
Across 82 payments — averaging $129.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$5K
- E.r. Squibb & Sons, L.L.C.$3K
- Janssen Scientific Affairs, LLC$1K
- Bristol Myers Squibb$405
- Astellas Pharma US Inc$349
- AbbVie$273
- plus $1K from 20 others
What the payments were for
- Consulting fees$5,06048%
- Speaking & faculty fees$2,19521%
- Travel & lodging$1,20911%
- Food & beverage$1,50814%
- Education$6346%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 12 | $4,724 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,681 |
| Janssen Scientific Affairs, LLC | 2 | $1,106 |
| Bristol Myers Squibb | 7 | $405 |
| Astellas Pharma US Inc | 6 | $349 |
| AbbVie | 12 | $273 |
| AstraZeneca | 3 | $127 |
| Eisai Inc. | 1 | $125 |
| Amgen | 1 | $100 |
| Gilead | 5 | $93 |
| Novartis | 5 | $87 |
| Seagen Inc. | 1 | $83 |
| Karyopharm Therapeutics Inc. | 3 | $62 |
| Genentech USA, Inc. | 3 | $59 |
| Jazz Pharmaceuticals Inc. | 3 | $51 |
| Beigene USA, Inc. | 3 | $49 |
| Acrotech Biopharma Inc. | 3 | $40 |
| Tempus AI, Inc | 1 | $30 |
| CTI Biopharma Corp. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Dova Pharmaceuticals | 1 | $23 |
| Sanofi | 1 | $22 |
| Emmaus Medical, Inc. | 1 | $22 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Merck | 1 | $16 |
| Verastem, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,606 in reported general payments places this provider in the 80th percentile of 27 hematology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 18 | $266,857 |
| Lenalidomide | 19 | $190,568 |
| VenclextaVenetoclax | 17 | $50,110 |
| Imatinib Mesylate | 12 | $965 |
| ValacyclovirValacyclovir Hcl | 20 | $741 |
| Ondansetron OdtOndansetron | 21 | $390 |
| Prochlorperazine Maleate | 25 | $347 |
| Hydroxyurea | 21 | $323 |
| Fluconazole | 14 | $281 |
| Levofloxacin | 27 | $227 |
| Acyclovir | 30 | $210 |
| Oxycodone Hcl | 12 | $106 |
| Allopurinol | 17 | $77 |
| Prednisone | 19 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $405 | $266,85718 claims |
| AbbVieVenclexta | $273 | $50,11017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 27 hematology providers in Oregon.
Other hematology in Portland
- John GodwinPortland$52K
- Rebecca SilbermannPortland$26K
- Jessica LeonardPortland$26K
- Ronan SwordsPortland$11K
- Andy ChenPortland$11K
- Guang FanPortland$7K
- Rachel CookPortland$7K
- Anusha VallurupalliPortland$5K
- Elizabeth MillerPortland$3K
- Emma ScottPortland$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.